Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price rose 1.4% during mid-day trading on Thursday . The stock traded as high as $26.01 and last traded at $25.6980. Approximately 30,467,969 shares changed hands during trading, a decline of 26% from the average daily volume of 41,227,309 shares. The stock had previously closed at $25.34.
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer highlighted several new oncology pipeline developments, including an update to its lung cancer study, progress in an early bladder cancer combination trial with Astellas, and a new advanced lung cancer combo study. These announcements reinforce Pfizer’s growth prospects in cancer, a key area investors are watching for future revenue. Article Title
- Positive Sentiment: Pfizer also announced a license agreement with Chai Discovery to accelerate drug discovery using AI, suggesting management is investing in faster, more efficient R&D capabilities that could improve long-term pipeline productivity. Article Title
- Positive Sentiment: At ASCO 2026, Pfizer presented strong Phase 3 oncology data for its BRAFTOVI and TALZENNA combinations, adding more evidence that the company’s cancer franchise could support longer-term growth. Article Title
- Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, which is typically viewed as a routine investor-update event rather than a major new catalyst. Article Title
- Neutral Sentiment: Several articles focused on Pfizer’s dividend appeal and comparisons with peers such as Bristol Myers Squibb and Merck, but these were mostly valuation/income-investing discussions rather than direct stock-moving catalysts. Article Title
- Negative Sentiment: Separate coverage noted that Pfizer is still down meaningfully since its last earnings report, reflecting lingering investor concern about growth expectations and post-earnings momentum. Article Title
Analyst Ratings Changes
PFE has been the subject of several recent research reports. Guggenheim boosted their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research report on Monday. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.82.
Pfizer Stock Performance
The business has a 50 day moving average of $26.68 and a 200 day moving average of $26.29. The company has a market capitalization of $146.46 billion, a P/E ratio of 19.62 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio is 131.30%.
Institutional Investors Weigh In On Pfizer
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Norges Bank purchased a new stake in Pfizer during the fourth quarter valued at approximately $1,830,986,000. Morgan Stanley raised its position in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp raised its position in Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. raised its position in Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Janus Henderson Group PLC raised its position in Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
